No spam - just the good stuff

Subscribe to our newsletter

News

Neural

Study linking heart health to brain health could delay dementia

Nano drug-delivery system developed for neurological disorders

Longevity Escape Velocity within 10 years?

Bestselling book enters new markets and predicts Longevity Escape Velocity by 2029/30.

Rise of the superagers – sharp minds and youthful cognition

A year in Longevity: progress perspectives

Neurotech2020 – bringing Longevity to a head

Defining Alzheimer’s by biomarkers could improve clinical trials

Neurotech2020 – a clear head for neurotech, research and investment

Found: the missing link in the Longevity ‘supply-chain’

Novel pathway to cracking the Alzheimer’s puzzle

Neurotech2020: It’s a brave new world

Stopping neurodegeneration in its tracks with ozone therapy

Exclusive video interview with Dave Asprey

Neuralink reveals the “Fitbit for your brain”

Brain circuitry research key to tailored neurological treatments

New blood test diagnoses Alzheimer’s Disease decades before symptoms

Bridging the gap: artificial to biological neuron interfacing

Ultra-light tattoo electrodes offer breakthrough in brain monitoring

Neurotech is the new blue ocean

Longevity and the Singularity

Making the Longevity grade: expanded list of 1000 leading names

Longevity and the art of motorcycle maintenance

Longevity2020: Day 3 recap

Longevity 2020: shaping-up nicely

Biological and artificial neurons linked using standard IP

Some good news: announcing Longevity2020

Wired for sound: neuroceutical boosts immunity

Nutraceuticals to beat cognitive decline before it starts

J&J enters Longevity market with “Immorbidity” play

NeuroTech Analytics releases industry-first report

Integrating mind and machine: Closer to singularity?

2020 outlook for Longevity technology

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.